Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Opthea ( (AU:OPT) ).
Opthea Limited has announced a change in its registered office and principal place of business, moving from South Yarra, Victoria, to a new location in Melbourne, Australia. This corporate update signifies a strategic shift in the company’s operations, potentially impacting its logistical and administrative functions, while maintaining the same communication channels.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company’s primary product targets the treatment of retinal diseases, aiming to address significant unmet medical needs in ophthalmology.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$738.8M
Learn more about OPT stock on TipRanks’ Stock Analysis page.